Zobrazeno 1 - 10
of 57
pro vyhledávání: '"M. Fevzi Ozkaynak"'
Autor:
M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Externí odkaz:
https://doaj.org/article/17b92398321047eeaf8c549f096a771f
Autor:
M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel, Alice L. Yu
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
PurposeA phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was desig
Externí odkaz:
https://doaj.org/article/9bf5ab108c46412582e14a20102da357
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Supplementary Methods and Supplementary Table Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b69d4cac1b9a2be587c851224387691
https://doi.org/10.1158/1078-0432.22463705
https://doi.org/10.1158/1078-0432.22463705
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926f56ed51054308532a63e87b3333d2
https://doi.org/10.1158/1078-0432.c.6525485
https://doi.org/10.1158/1078-0432.c.6525485
Autor:
Paul M. Sondel, Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Julie R. Park, John M. Maris, Michael D. Hogarty, Susan L. Cohn, Katherine K. Matthay, Stephen D. Gillies, Ralph A. Reisfeld, Mitchell B. Diccianni, Jacquelyn A. Hank, Arlene Naranjo, Wendy B. London, Patrick K. Reville, Dustin Hess, Yiqiang Song, Eneida A. Mendonça, KyungMann Kim, Lakeesha Carmichael, Wei Wang, Amy K. Erbe
Clinical characteristics of COG patients, according to treatment group, for all patients and for those genotyped for KIR/KIR-ligand.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a5bb83a24d9f4c6d3d04489706900e7
https://doi.org/10.1158/1078-0432.22463687
https://doi.org/10.1158/1078-0432.22463687
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Figure S1a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f0ff0ee0abecf0b93a4f3cba17f4438
https://doi.org/10.1158/1078-0432.22484007.v1
https://doi.org/10.1158/1078-0432.22484007.v1
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Figure S1a, Figure S1b; Supplementary Tables S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d54eeb58ba43ac859d741380368f48f8
https://doi.org/10.1158/1078-0432.22484001
https://doi.org/10.1158/1078-0432.22484001
Autor:
Paul M. Sondel, Julie R. Park, Rochelle Bagatell, John M. Maris, Susan L. Cohn, Katherine K. Matthay, Marguerite Parisi, Barry L. Shulkin, Malcolm Smith, Sheena C. Tenney, Wendy B. London, Ayse Batova, Jacquelyn A. Hank, Jacek Gan, Mitchell B. Diccianni, Arlene Naranjo, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu
Purpose:Previously our randomized phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children with high-risk neuroblastoma that had responded to induction and consolid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22aa2cb454ff0cd5cf051e4572a0bff8
https://doi.org/10.1158/1078-0432.c.6531294
https://doi.org/10.1158/1078-0432.c.6531294
Autor:
Julie R. Park, Sheena C. Tenney, Alice L. Yu, Paul M. Sondel, L. Mary Smith, Wendy B. London, Karen Messer, Marguerite T. Parisi, Arlene Naranjo, Robert C. Seeger, Mitchell B. Diccianni, Andrew L. Gilman, John M. Maris, M. Fevzi Ozkaynak, Malcolm A. Smith, Barry L. Shulkin, C. Patrick Reynolds
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology
Frontiers in Immunology
Purpose: A Phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was des
Autor:
Mitchell S. Cairo, Jessica Hochberg, M. Fevzi Ozkaynak, Lauren Harrison, Alfred P. Gillio, Alexandra Cheerva, Theodore B. Moore, Jennifer Krajewski, Julie Talano, Lee Ann Baxter-Lowe, Stacey Zahler, O. Militano, Nan Chen, Mark C. Walters, Mark B. Geyer, Carl V. Hamby
Publikováno v:
Bone marrow transplantation, vol 54, iss 2
Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival